(S)-5-甲氧基-1,2,3,4-四氢-N-(苯甲基)-2-萘胺 | 58349-23-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: (S)-5-甲氧基-1,2,3,4-四氢-N-(苯甲基)-2-萘胺
• 中文别名: (S)-5-甲氧基-1,2,3,4-四氢-N-(苯甲基)-2-萘胺(罗替戈汀)；(S)-5-甲氧基-1,2,3,4-四氢-N-(苯甲基)-2-萘胺 (罗替戈汀)
• 英文名称: (S)-(-)-2-(N-benzylamino)-5-methoxytetralin
• 英文别名: (-)-2-(benzylamino)-5-methoxytetralin；N-benzyl-N-[(2S)-5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]amine；(2S)-N-benzyl-5-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine
• CAS: 58349-23-8
• 化学式: C₁₈H₂₁NO
• 分子量: 267.371
• InChiKey: OZFLGQHJVWSALN-INIZCTEOSA-N

物化性质

• 沸点：
  424.4±45.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  (S)-5-甲氧基-1,2,3,4-四氢-N-(苯甲基)-2-萘胺 在 水 、 氢溴酸 、 氨 作用下， 以 水 为溶剂， 反应 4.5h， 以91%的产率得到(6S)-6-[benzylamino]-5,6,7,8-tetrahydronaphthalen-1-ol
  参考文献：
  名称：

  Combination of a 5-HT7 receptor ligand and an opioid receptor ligand

  摘要：

  本发明涉及一种5HT7受体配体和阿片受体配体的组合，特别是一种5HT7受体激动剂和阿片受体激动剂，包含该组合的药物，或者利用该组合治疗疼痛症状，预防或预防疼痛症状的用途。

  公开号：

  EP1997493A1
• 作为产物：
  描述：

  5-甲氧基-2-萘满酮 在 platinum(IV) oxide 氢气 、 对甲苯磺酸 作用下， 反应 3.0h， 生成 (S)-5-甲氧基-1,2,3,4-四氢-N-(苯甲基)-2-萘胺
  参考文献：
  名称：

  Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands

  摘要：

  Fluorescent probes have been designed and developed for dopamine D-1 and D-2 receptors. Fluorescein and/or NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl) derivatives of PPHT (D-2 agonist), spiperone (D-2 antagonist), SKF 38393 (D-1 agonist), and SKF 83566 (D-1 antagonist) were synthesized via their amino-functionalized analogues and all ligands were pharmacologically evaluated by measuring their ability to displace [H-3]SCH 23390 and [H-3]spiperone from D-1 and D-2 receptor sites in caudate putamen of monkeys (Macaca fascicularis). The fluorescein derivatives of PPHT and SKF 83566 and the NBD derivatives of spiperone and SKF 83566 retained the high affinity and selectivity of the parent ligands. The NBD derivatives of PPHT showed higher D-2 receptor affinity and selectivity than their parent ligands. The enantiomers of the fluorescent derivatives of PPHT were also synthesized and were found to exhibit stereoselectivity in binding to the D-2 receptor, with the S enantiomers having a considerably higher affinity than their R analogues. In contrast to these results, the fluorescein derivative of SKF 38393 showed only a low affinity for the D-1 receptor. These fluorescein- and NBD-coupled D-1 and D-2 receptor ligands have considerable significance as potential probes in the study of distribution of the receptors at the cellular/subcellular level and of their mobility in membranes in normal/diseased states by use of fluorescence microscopic and fluorescence photobleaching recovery techniques, respectively. The development of these novel fluorescent probes should also provide new leads for the design and synthesis of additional fluorescent ligands with better fluorescent properties and/or higher affinity/selectivity for the DA receptors.

  DOI：

  10.1021/jm00115a012

文献信息

• Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1956006A1

  公开（公告）日：2008-08-13

  The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I) and (Iprot), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals, mediated by the receptor 5-HT7 affinity.

  本发明涉及一般式（I）和（Iprot）的杂环基取代的四氢萘化合物，其制备方法，包含这些化合物的药物，以及它们用于制备用于治疗人类或动物的药物，通过5-HT7受体亲和力介导。
• PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS
  申请人：Marquillas Olondriz Francisco

  公开号：US20110152543A1

  公开（公告）日：2011-06-23

  The present invention describes a novel process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds based on the optical resolution of mixtures of the enantiomers of 2-(N-propylamino)-5-methoxytetraline and 2-(N-propylamino)-5-hydroxytetraline respectively. This process comprises (a) reacting a mixture of the enantiomers of said compounds with an optically active organic acid to form diastereoisomeric salts and separating the salts by crystallization. Said compounds are useful in the preparation of (6S)-(−)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine). Rotigotine is a dopamine agonist and is indicated for the treatment of Parkinson's disease.

  本发明描述了一种新颖的制备手性活性(S)-(−)-2-(N-丙基氨基)-5-甲氧基四氢喹啉和(S)-(−)-2-(N-丙基氨基)-5-羟基四氢喹啉化合物的方法，该方法基于对2-(N-丙基氨基)-5-甲氧基四氢喹啉和2-(N-丙基氨基)-5-羟基四氢喹啉的对映体混合物进行光学分辨。该过程包括(a)将所述化合物的对映体混合物与手性活性有机酸反应，形成非对映异构盐，并通过结晶分离盐。这些化合物在(6S)-(−)-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘酚（洛地吉酮）的制备中是有用的。洛地吉酮是一种多巴胺激动剂，用于治疗帕金森病。
• [EN] PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE COMPOSÉS (S)-(-)-2-(N-PROPYLAMINO)-5-MÉTHOXYTÉTRALINE ET (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTÉTRALINE OPTIQUEMENT ACTIFS
  申请人：INTERQUIM SA

  公开号：WO2010043571A1

  公开（公告）日：2010-04-22

  The present invention describes a novel process for the preparation of optically active (S)-(-)-2-(N-propylamino)-5-methoxytetraline and (S)-(-)-2-(N-propylamino)-5- hydroxytetraline compounds based on the optical resolution of mixtures of the enantiomers of 2-(N-propylamino)-5-methoxytetraline and 2-(N-propylamino)-5- hydroxytetraline respectively. This process comprises (a) reacting a mixture of the enantiomers of said compounds with an optically active organic acid to form diastereoisomeric salts and separating the salts by crystallization. Said compounds are useful in the preparation of (6S)-(-)-5,6,7,8-tetrahydro-6-[propyl-(2- thienyl)ethyl]amino-1 -naphthol (Rotigotine). Rotigotine is a dopamine agonist and is indicated for the treatment of Parkinson's disease.

  该发明描述了一种新颖的工艺，用于制备光学活性的(S)-(-)-2-(N-丙基氨基)-5-甲氧基四氢吲哚和(S)-(-)-2-(N-丙基氨基)-5-羟基四氢吲哚化合物，该工艺基于对2-(N-丙基氨基)-5-甲氧基四氢吲哚和2-(N-丙基氨基)-5-羟基四氢吲哚两种对映体混合物的光学分辨。该工艺包括：(a)将这些化合物的对映体混合物与光学活性有机酸反应，形成异构盐，并通过结晶分离这些盐。这些化合物在(6S)-(-)-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘酚（洛地吉酮）的制备中有用。洛地吉酮是一种多巴胺激动剂，用于治疗帕金森病。
• HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS
  申请人：Garcia-Lopez Monica

  公开号：US20100035936A1

  公开（公告）日：2010-02-11

  The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I), methods for their preparation, and compositions comprising these compounds as well as their use for the treatment or prophylaxis of various disorders in humans or animals.

  本发明涉及一般式（I）的杂环取代四氢萘烯化合物，其制备方法，以及包含这些化合物的组合物，以及它们在治疗或预防人类或动物的各种疾病中的使用。
• HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS
  申请人：Garcia-Lopez Monica

  公开号：US20100105684A1

  公开（公告）日：2010-04-29

  The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen-amine compounds of general formula (I) and compositions thereof, methods for their preparation, and the use of said compounds for the treatment or prophylaxis of various disorders of humans or animals.

  本发明涉及一般式(I)的杂环取代四氢萘胺化合物及其组合物，其制备方法以及利用该化合物治疗或预防人或动物的各种疾病。